Low-dose stavudine trials: A public health priority for developing countries

Southern African Journal of HIV Medicine

Volumn , Issue 43, 2012, Pages 20-21

  Venter, W D Francois ^a   Innes, Steve ^b   Cotton, Mark ^b  

^a UNIVERSITY OF THE WITWATERSRAND   (South Africa)

^b STELLENBOSCH UNIVERSITY   (South Africa)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; ANTIRETROVIRUS AGENT; EFAVIRENZ; RALTEGRAVIR; STAVUDINE; TENOFOVIR; ZIDOVUDINE;

DEVELOPING COUNTRY; DIALYSIS; DRUG BIOAVAILABILITY; DRUG COST; DRUG EFFICACY; DRUG SAFETY; DRUG SURVEILLANCE PROGRAM; GOLD STANDARD; HUMAN; HYPERSENSITIVITY REACTION; LOW DRUG DOSE; NEPHROTOXICITY; PRACTICE GUIDELINE; PUBLIC HEALTH; SHORT SURVEY;

EID: 84860782217     PISSN: 16089693     EISSN: None     Source Type: Journal    
DOI: 10.4102/sajhivmed.v13i1.154     Document Type: Short Survey

References (12)

1. Innes S, Cotton M, Venter F. Why should we still care about the stavudine dose? Southern African Journal of HIV Medicine 2011;12(4):14-15.
2. Scherzer R, Estrella M, Li Y, Deeks SG, Grunfeld C, Shlipak MG. Association of tenofovir exposure with kidney disease risk in HIV infection. AIDS 2012 [Epub ahead of print, 4 Feb].
3. Makinson A, Moing VL, Kouanfack C, Laurent C, Delaporte E. Safety of stavudine in the treatment of HIV Infection with a spedal focus on resource-limited settings. Expert Opin Drug Saf 2008;7(3):283-293. (Pubitemid 351802828)
4. Pujades-Rodríguez M, Dantony E, Pinoges L, et al. AIDS Working Group of Médecins Sans Frontières. Toxicity associated with stavudine dose reduction from 40 to 30 mg in first-line antiretroviral therapy. PLoS One 2011;6(11):e28112 [Epub 21 Nov 2011].
5. Hill A. d4T: keep it or abandon it? Asian Biomedkine 2010;4(4):541-546.
6. Boulle A, Orrell C, Kaplan R, et al. Substitution due to antiretroviral toxicity or contraindication in the first 3 years of antiretroviral therapy in a large South African cohort. AntrvirTher 2007;12:753-760. (Pubitemid 47235489)
7. George JA, Venter WD, Van Deventer HE, Crowther NJ. A longitudinal study of the changes in body fat and metabolic parameters in a South African population of HIV-positive patients receiving an antiretroviral therapeutic regimen containing stavudine. AIDS Res Hum Retroviruses 2009;25(8):771-781.
8. Innes S, Levin L, Cotton M. Lipodystrophy syndrome in HIV-infected children on HAART. South African Journal of HIV Medicine 2009;10(4):76-80.
9. Bobat R, Kindra G, Kiepiela P, et al. Use of abacavir in 30 HIV-infected children from Durban, South Africa: report from a pilot study. Pediatr Infect Dis J 2010;29(9):890.
10. Spaulding A, Rutherford GW, Siegfried N. Stavudine or zidovudine in three-drug combination therapy for initial treatment of HIV infection in antiretroviral-naïve individuals. Cochrane Database Syst Rev 2010 Aug 4;(8):CD008651.
11. Eley B. Metabolic complications of antiretroviral therapy in HIV-infected children. Expert Opin Drug Metab Toxicol 2008;4(1):37-49. (Pubitemid 351234099)
12. Rabie H, Henning KL, Schoeman P, DeVilliers N, Pretorius GHJ, Cotton M. Abacavir: it use and hypersensitivity. Southern African Journal of HIV Medicine 2009;10(4):81-84.